Eli Lilly's diabetes drug Mounjaro is set to be included in China's national health insurance reimbursement list, boosting accessibility but with potential revenue impact from pricing adjustments.
Eli Lilly's Mounjaro joins China's national health insurance list for type 2 diabetes, enhancing accessibility amid pricing adjustments. Related diabetes therapies and market impacts examined.
China launches its first Commercial Health Insurance Innovative Drug List with CAR-T therapies, advancing access to innovative cancer and rare disease treatments under commercial insurance.
CMS expands Medicare drug price controls to 25 medications, achieving $12 billion savings with new Maximum Fair Prices starting 2026 and 2027 for chronic and cancer treatments.
CMS announces $12 billion savings from Medicare drug price negotiations on 15 high-cost medications, effective 2027, enhancing Medicare Part D sustainability.
The FDA has reassigned the director of its Office of Nonprescription Drugs to a medical devices leadership role, highlighting a strategic shift toward affordability and regulatory realignment. This change may impact drug approval policies and insurance regulatory compliance.
CMS sets 2027 maximum fair prices for 15 high-cost Medicare drugs, cutting costs by up to 85% and saving $12 billion annually under Inflation Reduction Act measures.
Novo Nordisk's semaglutide drugs face significant Medicare price reductions under CMS negotiation rules starting 2027, but new indications could drive future revenue growth.
The federal government lowers obesity drug prices and expands Medicare coverage, impacting millions of patients and primary care providers with new access and cost structure.
New Medicare drug price negotiations under the Inflation Reduction Act cut costs for 15 major medications, saving Medicare $12 billion annually.
